Drugs / LV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06501664 | Aug 2024 → Nov 2026 expected | esophageal squamous cell carcinoma | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06501664 ↗ |